Company news
Medicenna Therapeutics Corp. (TSX:MDNA) news
Medicenna Therapeutics Corp. news releases on 6ix. Latest, Mar 27, 2019: Medicenna to Present at the Spring Investor Summit on April 1st and 2nd in New York…
Press releases — page 3
Medicenna to Present at the Spring Investor Summit on April 1st and 2nd in New York City at the Essex House
March 27, 2019
Medicenna Reports Third Quarter Fiscal 2019 Financial Results
February 14, 2019
Medicenna Presents Promising Clinical Data from Phase 2b Recurrent Glioblastoma Trial of MDNA55
February 7, 2019
Medicenna Shows Promising Pre-Clinical Results in Solid Tumor Models with its IL-2 Superkine, MDNA109
February 6, 2019
Medicenna to Host Virtual Roadshow Webinar
January 25, 2019
Preliminary Results on MDNA55 and MDNA109 to be Presented at the Immuno-Oncology 360° Conference
January 24, 2019
Medicenna Announces Closing of Previously Announced Public Offering
December 21, 2018
Medicenna Receives US$1.2 Million Non-Dilutive Grant Payment
December 5, 2018
Medicenna Reports Second Quarter Fiscal 2019 Financial Results
November 13, 2018
Medicenna Announces Marketed Offering of Units
November 8, 2018
Medicenna to Present at Upcoming Scientific Conferences
November 7, 2018
Medicenna Provides Positive Interim Update From Phase 2b Trial of MDNA55 in Recurrent Glioblastoma
October 31, 2018
Medicenna Presented Insights from the Phase 2b Clinical Trial of MDNA55 at the European Society for Medical Oncology 2018 Congress
October 22, 2018
Medicenna to Present MDNA55 Clinical Results at ESMO Congress
October 16, 2018
Medicenna Solidifies Patent Protection For Long-Acting IL-2 Superkines
September 27, 2018
Medicenna to Present IL-2 Superkine Results at the Sixth Annual Immuno-Oncology Summit
August 28, 2018
Medicenna Reports First Quarter Fiscal 2019 Financial Results
August 13, 2018
Medicenna Provides Development Update on MDNA109 IL-2 Superkine Program
August 2, 2018
Medicenna Strengthens Empowered Cytokine(TM) Platform with Notice of Allowance of US Patent
July 25, 2018
Medicenna Announces March 31, 2018 Year-End Results and Provides Update on Clinical Program
June 27, 2018
Medicenna to Present at 4th Annual Immuno-Oncology: BD&L and Investment Forum
May 29, 2018
Medicenna Amends Protocol of Phase 2b Recurrent Glioblastoma Study of MDNA55 in Response to Strong Safety Data and Early Efficacy Read-outs
May 2, 2018
Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2018
April 25, 2018
Medicenna Reports Third Quarter Fiscal 2018 Financial Results
February 12, 2018
Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology
November 16, 2017
Medicenna Presents Clinical Data From Previous Phase 1 and 2 Clinical Trials of MDNA55
November 14, 2017
Medicenna Reports Second Quarter Fiscal 2018 Financial Results
November 13, 2017
Medicenna Announces Presentations at the 2017 Annual Meeting of the Society of Neuro-Oncology
November 9, 2017
Medicenna Announces Presentation at the 2017 Innovations In Cancer Prevention and Research Conference
October 31, 2017
Medicenna Solidifies Superkine Platform with Additional US Patent Issuance
October 24, 2017
Medicenna Announces Trading on the OTCQX Best Market in the United States
October 18, 2017
Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA55
October 10, 2017
Medicenna Updates On-Going Phase 2b Clinical Trial Protocol for Recurrent Glioblastoma
September 28, 2017
Medicenna Announces Late Breaking Oral Presentation at the 2017 Congress of Neurological Surgeons (CNS) Annual Meeting
September 25, 2017
Medicenna Appoints Dr. William Li to Board of Directors
September 21, 2017
Medicenna to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
September 6, 2017
Medicenna Reports First Quarter Fiscal 2018 Financial Results
August 9, 2017
Medicenna Announces Graduation to the TSX
August 1, 2017
Medicenna Bolsters Management Team
July 17, 2017
Medicenna Announces March 31, 2017 Year End Results
June 16, 2017
Medicenna's Immunotherapy Phase 2b Trial Underway Using Brainlab Drug Delivery Technology
June 8, 2017
Medicenna Therapeutics Corp. Opens the Market
May 25, 2017
Medicenna Therapeutics Opens the Market
May 25, 2017
Medicenna Strengthens Patent Portfolio for its Lead Clinical Candidate, MDNA55
April 27, 2017
Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2017
April 20, 2017
Medicenna Treats First Patient in Phase 2b Recurrent Glioblastoma Trial
April 13, 2017
Medicenna BioPharma Announces Strategic Collaboration with MD Anderson Cancer Center to Advance Next Generation Empowered Cytokines(TM)
March 16, 2017
Medicenna shares resume trading under the symbol "MDNA"
March 8, 2017
IIROC Trading Resumption - AFCC; BTRU; LMC; MDNA; PGZ
March 7, 2017
IIROC Trade Resumption - Medicenna Therapeutics Corp.
March 7, 2017